Should patients stop taking other medications when starting GLP-1 therapy
Dec 2014;44(12):1159-1168
Animal studies All rodent studies were approved either by the Gteborg Preclinical Ethical Committee for AstraZeneca (Sweden), the Institutional Animal Care and Use Committee at MedImmune (Gaithersburg, MD, USA) in accordance with US Animal Welfare Act guidelines, Home Office licences for studies performed at MedImmune (Cambridge, UK), or under personal licenses issued by the Danish Committee for Animal Research for studies performed at Gubra (Horsholm, Denmark)
There are recent reports of eye problems following use of semaglutide, Monitoring of nursling for side effects Although adverse effects have not been noted the baby should be monitored for decreased appetite, abdominal distension, GERD, constipation, diarrhoea
and solicit any necessary supplemental information
10.1038/33416 Nature 55 KlionskyD